Development of Tight Junction Reversible Opener for Non-Invasive Drug Administration: Drug Administration without Injection
نویسندگان
چکیده
منابع مشابه
Mass drug administration for malaria
BACKGROUND Mass drug administration (MDA), defined as the empiric administration of a therapeutic antimalarial regimen to an entire population at the same time, has been a historic component of many malaria control and elimination programmes, but is not currently recommended. With renewed interest in MDA and its role in malaria elimination, this review aims to summarize the findings from existi...
متن کاملProliposomes for oral drug administration.
The oral route of drug administration is generally preferred because of its versatility, safety and relative patient comfort. Liposomes have received much attention for their usefulness in reducing toxicity and improving therapeutic effectiveness. Although liposomes are a most promising, broadly applicable, and highly researched novel delivery system, they suffer from serious stability problems...
متن کاملDevelopment of Novel Arrayed Microjet Devices for Transdermal Drug Administration
SUMMARY The micro-arrayed needle-free injector technology being developed for trans-dermal vaccine administration is based on PARC’s work on ballistic aerosol marking, which was originally developed as an alternative to conventional ink-jet printing. The underlying idea behind it was to use high speed air jets (at sonic to supersonic speeds) in order to accelerate entrained toner particles at s...
متن کاملThe Food and Drug Administration and the Future of Drug Development for the Treatment of Diabetes.
The U.S. Food and Drug Administration (FDA) regulates the marketing of drugs in the United States. The FDA staff faces substantial challenges in evaluating preclinical and clinical trial data for a proposed new drug and deciding whether the resultant benefit-risk assessment supports marketing approval. Any approval decision will be associated with uncertainty regarding the drug's true risks and...
متن کاملRadium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. The FDA review was based on clinical trial BC1-06, which randomly allocated patients ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: KAGAKU TO SEIBUTSU
سال: 2020
ISSN: 0453-073X,1883-6852
DOI: 10.1271/kagakutoseibutsu.58.204